We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Coagulation Properties of Fresh Blood Lasts Longer Than Assumed

By LabMedica International staff writers
Posted on 17 Mar 2011
The blood clotting properties of refrigerated whole blood may have a shelf life well beyond the current standard of 24 to 48 hours. More...


The majority of patients receiving blood transfusions only require specific components of whole blood, such as red blood cells, plasma and platelets and the coagulation properties are thought to decline rapidly.

A study carried out at The Children's Hospital of Philadelphia, (Philadelphia, PA, USA), examined the freshness of whole blood with respect to its clotting properties in 21 units of blood from healthy volunteer donors. The units of blood were stored under standard conditions as mandated by the American Association of Blood Banks, (AABB; Bethesda, MD, USA). Samples were obtained on the day after donation and again on days 2, 4, 7, 11, 14, 17, 21, 24, and 31. Tests included complete blood count, pH, partial pressures of oxygen and carbon dioxide (pO2, pCO2), glucose, lactate, thromboelastography (TEG), and platelet function by light transmission aggregometry (LTA).

The current practice at The Children's Hospital of Philadelphia assumes a fresh whole blood shelf life of 48 hours when refrigerated. After that point, the erythrocytes may be recovered from the whole blood, but the other components, such as plasma and platelets must be discarded. However, the scientists found that TEG and platelet aggregation levels, which measure the efficiency of blood coagulation, remain normal at least 11 days under standard refrigerated conditions.

David Jobes, MD, a cardiothoracic anesthesiologist at the hospital, said, "Trauma patients could potentially benefit, as well as others needing a large volume of blood replacement, such as patients undergoing liver transplant or children who need craniofacial reconstruction. The results of the study strongly suggest that clinical trials should proceed to test the value of whole blood beyond a 48-hour period." The study was published in January 2011, in the journal Transfusion.

Related Links:

The Children's Hospital of Philadelphia

American Association of Blood Banks





Gold Member
Hematology Analyzer
Medonic M32B
Portable Electronic Pipette
Mini 96
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Gold Member
Hematology System
Medonic M16C
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.